{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:41:05Z","timestamp":1791200465865,"version":"4.2.0"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,4,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> There are few treatment options for patients with metastasized or inoperable endocrine gastroenteropancreatic (GEP) tumors. Chemotherapy can be effective, but the response is usually less than 1 year. Here, we present the results of treatment with a radiolabeled somatostatin analog, [<jats:sup>177<\/jats:sup>Lu-DOTA<jats:sup>0<\/jats:sup>,Tyr<jats:sup>3<\/jats:sup>]octreotate (<jats:sup>177<\/jats:sup>Lu-octreotate). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> One hundred thirty-one patients with somatostatin receptor-positive tumors were treated with up to a cumulative dose of 600 to 800 mCi (22.2 to 29.6 GBq) of <jats:sup>177<\/jats:sup>Lu-octreotate. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> One patient developed renal insufficiency, and another patient developed hepatorenal syndrome. Creatinine clearance did not change significantly in the other patients. WHO hematologic toxicity grade 3 or 4 occurred after less than 2% of the administrations. We observed complete remission in three patients (2%), partial remission in 32 patients (26%), minor response (tumor diameter decrease of 25% to 50%) in 24 patients (19%), stable disease (SD) in 44 patients (35%), and progressive disease (PD) in 22 patients (18%). Higher remission rates were positively correlated with high uptake on pretherapy somatostatin receptor imaging and a limited number of liver metastases, whereas PD was significantly more frequent in patients with a low performance score and extensive disease. Median time to progression in 103 patients who either had SD or tumor regression was more than 36 months. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Treatment with <jats:sup>177<\/jats:sup>Lu-octreotate results in tumor remission in a high percentage of patients with GEP tumors. Serious side effects are rare. The median time to progression compares favorably with chemotherapy. Results are better in patients with a limited tumor load. Therefore, early treatment, even in patients who have no PD, may be better. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.08.066","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T22:38:08Z","timestamp":1113863888000},"page":"2754-2762","source":"Crossref","is-referenced-by-count":551,"title":["Radiolabeled Somatostatin Analog [<sup>177<\/sup>Lu-DOTA<sup>0<\/sup>,Tyr<sup>3<\/sup>]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors"],"prefix":"10.1200","volume":"23","author":[{"given":"Dik J.","family":"Kwekkeboom","sequence":"first","affiliation":[{"name":"From the Departments of Nuclear Medicine, Internal Medicine, and Surgery, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap J.","family":"Teunissen","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear Medicine, Internal Medicine, and Surgery, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem H.","family":"Bakker","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear Medicine, Internal Medicine, and Surgery, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Kooij","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear Medicine, Internal Medicine, and Surgery, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear Medicine, Internal Medicine, and Surgery, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear Medicine, Internal Medicine, and Surgery, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper H.","family":"van Eijck","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear Medicine, Internal Medicine, and Surgery, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Paul","family":"Esser","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear Medicine, Internal Medicine, and Surgery, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boen L.","family":"Kam","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear Medicine, Internal Medicine, and Surgery, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Krenning","sequence":"additional","affiliation":[{"name":"From the Departments of Nuclear Medicine, Internal Medicine, and Surgery, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1159\/000201081"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869309083916"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03210.x"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1053\/snuc\/2002.31025"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1053\/snuc.2002.31769"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011160913619"},{"key":"R7","unstructured":"Waldherr C, Pless M, Maecke HR, et al: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:617,2002-620,"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1002\/bip.10349"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-1023-y"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-1006-z"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Waldherr C, Schumacher T, Maecke HR, et al: Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med 29:S100,2002,  (suppl, abstr)","DOI":"10.1007\/s00259-001-0720-2"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050034"},{"key":"R13","unstructured":"Erion JL, Bugaj JE, Schmidt MA, et al: High radiotherapeutic efficacy of [Lu-177]-DOTA-Y(3)-octreotate in a rat tumor model. J Nucl Med 40:223P,1999,  (suppl, abstr)"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100574"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-1050-8"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1007\/BF00944177"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050476"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050535"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.142"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.11.727"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198011203032101"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202203260804"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P"},{"key":"R24","unstructured":"Van Hazel GA, Rubin J, Moertel CG: Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine. Cancer Treat Rep 67:583,1983-585,"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940301)73:5<1505::AID-CNCR2820730530>3.0.CO;2-V"},{"key":"R26","unstructured":"Ritzel U, Leonhardt U, Stockmann F, et al: Treatment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol 90:627,1995-631,"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1486"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.21"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1159\/000080747"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(96)90303-2"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1007\/BF00198436"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Jorda M, Ghorab Z, Fernandez G, et al: Low nuclear proliferative activity is associated with nonmetastatic islet cell tumors. Arch Pathol Lab Med 127:196,2003-199,","DOI":"10.5858\/2003-127-196-LNPAIA"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11739"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.08.066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:07:08Z","timestamp":1653512828000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.08.066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,20]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,4,20]]}},"alternative-id":["10.1200\/JCO.2005.08.066"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.08.066","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,20]]}}}